fashion -WSS

fashion

author：comprehensive 2025-09-27 23:52:52 - browse：77573

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Cassava Sciences’ Alzheimer’s clinical trials should be halted

WSS

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Smaller biotechs seek to piggyback on weight loss drug boom

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

STAT Summit: How researchers deal with rejection

Smaller biotechs seek to piggyback on weight loss drug boom

leisure time

fashion

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Study on Amgen’s bispecific immunotherapy produces positive data

Heart attack and stroke risk calculators need revising

Results on Novartis prostate cancer therapy could expand its use

After affirmative action ruling, medical educators look to 'holistic review'

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Apple is now the first public company to be valued at $3 trillion

See how much Covid

Medicare details structure of new drug price negotiation program

STAT Summit: Ending the crisis of Black deaths in the U.S.

focus

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Ionis drug prevents swelling attacks due to hereditary angioedema

Shifting the focus from loneliness to social health

The problems with dementia villages

Results on Novartis prostate cancer therapy could expand its use

Why a market frenzy over new weight loss drugs defies logic

hotspot

focus

focus

focus